Status unknownNCT03152708Updated Sep 21, 2017

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

An observational study in Glioblastoma, sponsored by CANbridge Life Sciences Ltd.. Status unknown. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by CANbridge Life Sciences Ltd. · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Other
Time perspective: Retrospective
Enrollment: 62
Sex: All

Study summary

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Conditions studied

Glioblastoma

Browse trials for

Glioblastoma 1,916

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Chinese GBM patients

Inclusion criteria

Chinese nationality
No limits on Gender and age
First diagnosed GBM
Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion criteria

Exclusion Criteria:

Other types of glioma by histological diagnosis
Tumor tissue not eligible for the central laboratory testing standard
No enough tumor tissue for the central laboratory test

Study design

Observational model: Other
Time perspective: Retrospective
Enrollment: 62 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

CD95 Ligand Positive Rate
Time frame: 0 day

Secondary outcomes

CpG2 Positive Rate
Time frame: 0 day

Study locations

No study locations are listed for this record.

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT03152708
Lead sponsor: CANbridge Life Sciences Ltd.
Responsible party: Sponsor
First posted: May 15, 2017
Start date: Nov 1, 2017 (estimated)
Primary completion: Dec 1, 2017 (estimated)
Completion: Dec 31, 2017 (estimated)
Last update: Sep 21, 2017

Study contacts

Jack Hou

Contact

jhou@canbridgepharma.com

00862152996609

Jinsong Wu, MD

principal investigator · Huashan Hospital

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glioblastoma→

Other studies from this sponsor

CANbridge Life Sciences Ltd.

Start the discussion